Kev rhuav tshem Peptide Barrier: Siab -Purity Orforglipron API (CAS 2212020-52-3) rau Oral Formulations
Aug 10, 2026
Tso lus
Ua txhaum Peptide Barrier: Engineering Small-Molecule Orforglipron API (CAS 2212020-52-3)
Ib daim ntawv R&D Whitepaper ntawm Tsis yog -Peptide GLP-1 Agonists, Oral Bioavailability, thiab yav tom ntej ntawm Kev Kho Mob Metabolic.
Txawm tias thawj zaug - tiam "qhov ncauj" peptides raug kev txom nyem los ntawm kev tsim cov kab mob lom. Lawv xav tau kev sib koom ua ke loj heev - kev tsim nrog kev nqus tau zoo (xws li SNAC), tswj hwm lub qhov rais yoo mov ua ntej thiab tom qab noj, thiab tseem tsuas yog ua tiav qhov tsis txaus siab ~ 1% kev ua haujlwm bioavailability.
Orforglipron (CAS 2212020-52-3)yog cov tshuaj dawb huv grail uas R&D cov thawj coj tau siv sijhawm kaum xyoo nrhiav. Nws tsis yog peptide. Nws yog ib qho muaj zog heev, hais lus bioavailableme me moleculeGLP-1 receptor agonist. Cov ntaub ntawv thev naus laus zis no nthuav tawm cov txheej txheem sib khi tshwj xeeb ntawm Orforglipron, nthuav tawm cov kev txwv ntawm cov txheej txheem peptide cuam tshuam, thiab qhia txog qhov tseeb, siab -purity me me-molecule chemical synthesis raws tu qauv ua tiav ntawm Xi'an Tihealth.
1. Molecular Architecture: Rewriting the Rules of GLP-1 Activation
Txhawm rau ua kom muaj txiaj ntsig zoo ntawm Orforglipron hauv cov kav dej lag luam yav tom ntej, cov thawj coj tshawb fawb yuav tsum nkag siab tias vim li cas cov molecules me me coj txawv txawv dua li peptides ntawm qib receptor. Orforglipron (C45H45F3N8O5) yog ib qho txuj ci tseem ceeb ntawm cov tshuaj chemistry niaj hnub no, tsim los ua kom zoo li kev soj ntsuam kev ua tau zoo ntawm 31-amino acid polypeptide uas siv tsuas yog compact, multi-ring organic qauv.
Kev tiv thaiv rau Proteolytic digestion
Tib neeg txoj hnyuv yog ib qho evolutionary gauntlet tsim los utterly obliterate proteins thiab peptides mus rau inert amino acids ntawm pepsin thiab pH tsawg gastric. Qhov ncauj peptide formulations cia siab rau brute force- dhau lub plab nrog pH buffers hauv zos kom yuam ib feem me me ntawm cov tshuaj los ntawm lub plab mucosa. Orforglipron, raws li cov khoom siv hluav taws xob me me, yog lub cev tiv thaiv kab mob proteolytic enzymes. Nws siv zog ua kom muaj sia nyob ib puag ncig acidic ntawm lub plab thiab tuaj yeem nqus tau los ntawm cov kab mob hauv plab hnyuv, ua tiav cov ntshav plasma concentrations uas sib tw parenteral kev xa khoom yam tsis tas yuav tsum tau ceev ceev ceev.
Biased Agonism thiab Receptor Internalization
Kev lig kev cai GLP-1 peptides khi rau qhov chaw orthosteric ntawm receptor, uas ua rau muaj kev cuam tshuam rau beta-arrestin recruitment. Cov lus teb lom neeg no ua rau cov receptor rau sab hauv (rub rov qab rau hauv lub cell), ua rau desensitization thiab toj siab hauv kev kho mob ua tau zoo nyob rau lub sijhawm. Orforglipron qhia tshwj xeebkev ncaj ncees agonism. Nws khi rau ib lub hnab tsho sib txawv ntawm GLP-1 receptor, ua kom muaj zog ntawm cAMP teeb liab txoj hauv kev rau lub zog ntawm insulin secretion thiab qab los noj mov, thaum txo qis beta -kev nrhiav neeg ua haujlwm. Qhov no txhais tau tias muaj kev ruaj ntseg, mus sij hawm ntev cellular rhiab heev.
Kev tshem tawm qhov Txias -Chain Requirement
Vim tias cov tshuaj peptides tau tuav ua ke los ntawm cov peptide tsis muaj zog, lawv denature sai ntawm chav tsev kub, yuav tsum tau them nqi tub yees los ntawm lub Hoobkas mus rau lub tsev muag tshuaj. Orforglipron nta lub zog, fluorinated organic scaffold. Nws yog thermodynamically ruaj khov, tiv taus oxidative degradation, thiab yuav tsum tau xoom txias - saw logistics. Qhov no ua rau txo qis cov nqi faib thoob ntiaj teb thiab ua kom cov neeg mob ua raws li kev cai.
2. Forensic Formulation Matrix: Me-Molecule vs. Oral Peptides
Rau cov pab pawg muag tshuaj, qhov kev txiav txim siab hloov ntawm SPPS- muab peptides rau me me - molecule APIs tau hloov pauv tag nrho cov kev lag luam ntawm kev siv tshuaj. Cov txheej txheem zoo ntawm Orforglipron tag nrho dismantle cov keeb kwm teeb meem ntawm qhov ncauj metabolic kev kho mob.
| Clinical & Pharmacokinetic Parameter | Legacy Oral Peptides (xws li Oral Semaglutide) | Xi'an Tihealth Orforglipron API (CAS 2212020-52-3) |
|---|---|---|
| Molecular Classification | Macromolecule Peptide (Hloov yooj yim) | Me Molecule (Robust Organic Scaffold) |
| Qhov ncauj Bioavailability | Tshwj xeeb qis (~ 0.8% txog 1.0%) | High Systemic Absorption; Tsis txhob Proteolysis |
| Formulation complexity | Mandates co-formulation nrog SNAC (Sodium Salcaprozate) | Muaj peev xwm tsim tau raws li cov qauv khoom noj hauv qhov ncauj (Tablets / Capsules) |
| Cov Cai Tswj Tus Neeg Mob | Kev yoo mov nruj (Tsis muaj zaub mov / dej rau 30 feeb tom qab- koob tshuaj) | Kev ywj pheej ntawm cov qhov rais ceev ceev ceev; mob siab heev -ua raws |
| Manufacturing Scalability | Txwv los ntawm qeeb, linear Solid-Phase Peptide Synthesis (SPPS) | Muaj peev xwm ua tau zoo ntawm cov tshuaj organic tshuaj synthesis |
3. Xi'an Tihealth Advantage: Mastery ntawm Chiral Organic Synthesis
Synthesizing ib complex, multi-ring me me molecule zoo li Orforglipron nthuav tawm cov kev sib tw loj heev piv rau kev rho tawm cov botanical compounds. Cov molecule muaj cov chaw tseem ceeb chiral thiab tshwj xeeb trifluoromethyl (-CF3) cov pab pawg uas tswj hwm nws txoj kev sib raug zoo rau GLP-1 receptor. Kev muab khoom los ntawm cov chaw soj ntsuam tsis tau lees paub feem ntau ua rau cov khoom sib xyaw sib xyaw los yog cov kuab tshuaj lom uas cuam tshuam rau kev siv tshuaj kho mob.
NtawmXi'an Tihealth Biotechnology Co., Ltd., peb ua tiav qhov kev tsis sib haum xeeb, ntau -cov txheej txheem organic synthesis raws tu qauv tsim los rau kev ua kom huv huv stereochemical thiab kev ruaj ntseg ib puag ncig:
Asymmetric Organocatalysis
Orforglipron txoj kev kho mob tau txais txiaj ntsig zoo nyob ntawm qhov tseeb 3D spatial kev npaj ntawm nws cov pab pawg ua haujlwm. Peb siv kev txiav-ntug asymmetric catalytic txoj kev los xyuas kom meej qhov kawg active tshuaj muaj nyob rau hauv lub enantiomeric tshaj (ee) mus txog 100%, tshem tawm biologically inactive los yog tej zaum yuav muaj teeb meem stereoisomers.
Solvent Recovery & USP<467>Tswj
Complex tshuaj synthesis keeb kwm generates hnyav hnyav pov tseg. Xi'an Tihealth ntiav cov tswv kaw -loop solvent recovery systems. Tom qab-crystallization, API yog raug rau lub tshuab nqus tsev nqus tsev vacuum, kom ntseeg tau tias cov kuab tshuaj seem poob qis qis dua qib 2 thiab Chav Kawm 3 qhov kev tswj hwm los ntawm Tebchaws Meskas Pharmacopeia (USP<467>).
LC-MS & NMR Kev Tshawb Fawb
Peb tsis cia siab rau cov ntsiab lus titrations. Txhua pawg ntawm Orforglipron raug soj ntsuam xyuas los ntawm Liquid Chromatography-Mass Spectrometry (LC-MS) thiab Nuclear Magnetic Resonance (NMR) spectroscopy kom paub meej qhov hnyav molecular thiab atomic connectivity, yielding uncompromising.Ntau dua lossis sib npaug rau 99.0% HPLC purity.
4. Muaj Daim Ntawv Thov Kev Ua Haujlwm rau Orforglipron API
Vim tias Orforglipron hla dhau cov txheej txheem nruj me ntsis ntawm peptides, nws qhib tau yooj yim heev thiab ua kom tiav cov khoom tiav rau cov kws kho mob thiab kev tshawb fawb sectors:
Ib zaug -Cov ntsiav tshuaj qhov ncauj txhua hnub rau kev tswj qhov hnyav
Lub hom phiaj tseem ceeb ntawm daim ntawv thov. Orforglipron API tuaj yeem muab sib xyaw nrog cov khoom siv tshuaj raws li tus qauv thiab muab tso rau hauv cov ntaub ntawv siv tshuaj hauv qhov ncauj, tshem tawm tag nrho cov kev xav tau ua ntej - puv auto-injector cwjmem thiab cov khoom phom sij bio- khib nyiab.
Kev Tshawb Fawb Kev Tshawb Fawb & Kev Tshawb Fawb Kev Kawm
Muab cov chaw tshawb fawb ywj pheej nrog rau kev ua kom huv si, ruaj khov me me -molecule GLP-1 analogue los kawm txog cov txheej txheem metabolic tshiab, cov khoom tiv thaiv neuroprotective, thiab cov txiaj ntsig ntawm cov hlab plawv yam tsis muaj qhov hloov pauv ntawm peptides.
Formulator & Procurement FAQ
Semaglutide yog 31-amino acid peptide uas yuav tsum tau muaj zog-Phase Peptide Synthesis (SPPS). Qhov no yog ib qho qeeb, cov txheej txheem kab uas txhua cov amino acid yuav tsum tau txuas mus txuas ntxiv; ib qho kev sib txuas tsis tu ncua ua rau txo qis qhov kawg tawm los thiab qhia cov impurities nyuaj. Orforglipron yog synthesized siv ib txwm organic chemistry. Nws cov kev tsim khoom tuaj yeem ua kom nce siab hauv cov khoom siv hluav taws xob loj nyob rau hauv tib lub sijhawm, txo qis lub sijhawm tsim khoom, ua kom tau txais txiaj ntsig zoo tshaj plaws, thiab txhim kho cov khoom lag luam thoob ntiaj teb.
Txawm hais tias muaj zog ntau dua li peptides, cov ntshiab organic molecules tseem xav tau kev tuav haujlwm. Ua raws li cov crystallization siab heev thiab lub tshuab nqus tsev kom qhuav, API tau ntim rau hauv cov chaw muag tshuaj - qib ntim ntim lossis ob npaug - txheej aseptic aluminium foil hnab nyob rau hauv ib qho inert nitrogen flush. Nws tseem nyob ruaj khov ntawm tus qauv chav ntsuas kub, hla qhov nruj 2℃mus rau 8℃txias -chain yuav tsum tau ntawm legacy GLP-1 analogues.
kiag li. Xi'an Tihealth ua haujlwm nruj me ntsis raws li ISO9001: 2015 thiab GMP- ua raws li cov txheej txheem rau peb cov khoom siv tshuaj. Txhua pawg xa tawm ntawm Orforglipron yog nrog los ntawm cov ntawv sau ua tiav, suav nrog Daim Ntawv Pov Thawj Kev Ntsuam Xyuas (COA), siab -HPLC chromatograms daws teeb meem, thiab GC cov kuab tshuaj residue cov ntaub ntawv los pab txhawb koj cov nqi qis R & D thiab kev tshuaj xyuas zoo.
Pioneer lub neej yav tom ntej ntawm kev kho qhov ncauj metabolic nrog siab -purity me-molecule APIs.
Thov HPLC Chromatogram & Bulk PricingSau los ntawm Wang Xueyan, Technical Operations & Formulation Strategy ntawm Xi'an Tihealth Biotechnology Co., Ltd.
* Kev lees paub tsis raug cai: Muab tshwj xeeb raws li qhov tsis muaj npe, kev tshawb fawb -qib Cov Khoom Siv Tshuaj (API). Cov koom haum kev yuav khoom tsuas yog lub luag haujlwm rau kev tsim kho zaum kawg, kev sim tshuaj ntsuam xyuas, thiab kev tswj hwm nruj raws li lawv txoj cai thoob ntiaj teb.*
Xa kev nug